Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated h...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Infect Drug Resist
Главные авторы: Toh, Zheng Quan, Kosasih, Jennie, Russell, Fiona M, Garland, Suzanne M, Mulholland, Edward K, Licciardi, Paul V
Формат: Artigo
Язык:Inglês
Опубликовано: Dove 2019
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6613616/
https://ncbi.nlm.nih.gov/pubmed/31308715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S178381
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы